122 related articles for article (PubMed ID: 37820046)
21. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
[TBL] [Abstract][Full Text] [Related]
22. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
23. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
24. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
25. Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
Khera S; Mahajan D; Barbind K; Dhingra S
Cancer Chemother Pharmacol; 2023 Apr; 91(4):331-336. PubMed ID: 36951972
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
Bhojwani D; Sabin ND; Pei D; Yang JJ; Khan RB; Panetta JC; Krull KR; Inaba H; Rubnitz JE; Metzger ML; Howard SC; Ribeiro RC; Cheng C; Reddick WE; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2014 Mar; 32(9):949-59. PubMed ID: 24550419
[TBL] [Abstract][Full Text] [Related]
27. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
[TBL] [Abstract][Full Text] [Related]
28. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
[TBL] [Abstract][Full Text] [Related]
29. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.
Tsurusawa M; Katano N; Yamamoto Y; Hirota T; Koizumi S; Watanabe A; Takeda T; Hatae Y; Yatabe M; Mimaya J; Gushiken T; Nishi K; Anami K; Kikuta A; Kanegane H; Asami K; Nishikawa K; Sekine I; Kawano Y; Iwai A; Furuyama T; Ijichi O; Miyake M; Mugishima H; Fujimoto T
Med Pediatr Oncol; 1999 Apr; 32(4):259-6. PubMed ID: 10102019
[TBL] [Abstract][Full Text] [Related]
30. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
31. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen.
Kroll M; Kaupat-Bleckmann K; Mörickel A; Altenl J; Schewel DM; Stanullal M; Zimmermann M; Schrappe M; Cario G
Haematologica; 2020 Apr; 105(4):1013-1020. PubMed ID: 31371414
[TBL] [Abstract][Full Text] [Related]
33. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
34. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
Tatsumoto C; Kawakami K; Nagayama J; Kawano H
Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
[TBL] [Abstract][Full Text] [Related]
35. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
36. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.
Mandal P; Samaddar S; Chandra J; Parakh N; Goel M
Indian J Hematol Blood Transfus; 2020 Jul; 36(3):498-504. PubMed ID: 32647424
[TBL] [Abstract][Full Text] [Related]
37. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
Refsum H; Wesenberg F; Ueland PM
Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
[TBL] [Abstract][Full Text] [Related]
38. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
39. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
